Patents by Inventor Hae-Sim PARK

Hae-Sim PARK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230416380
    Abstract: A humanized antibody or antigen-binding fragment thereof that binds to the human IL-5 receptor alpha subunit (IL-5R?), which is a receptor of human interleukin-5 (IL-5); a nucleic acid encoding the antibody or antigen-binding fragment thereof; a vector containing the nucleic acid; and a cell transformed with the vector are disclosed. A method for producing the antibody or antigen-binding fragment thereof; a conjugate containing the antibody or antigen-binding fragment thereof; a bispecific or multispecific antibody containing the antibody or antigen-binding fragment thereof; and a composition thereof are disclosed. Also disclosed are methods for preventing or treating an allergic disease, an inflammatory disease and/or a disease caused by an increase in eosinophils; and for diagnosis of allergic diseases, inflammatory diseases, and/or diseases caused by an increase in eosinophils.
    Type: Application
    Filed: September 10, 2021
    Publication date: December 28, 2023
    Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Yong Sung KIM, Hae-Sim PARK, Jung Eun KIM, Keunok JUNG, Dong-Hyun LEE
  • Publication number: 20230357415
    Abstract: An IL-4R?×IL-5R? bispecific antibody that simultaneously binds to interleukin (IL)-4 receptor a (IL-4R?, CD124) and IL-5 receptor a (IL-5R?, CD125) is provided. A multispecific antibody including the bispecific antibody, a nucleic acid encoding the bispecific antibody or multispecific antibody, a vector including the nucleic acid, and cells transformed by the vector are disclosed. Additionally, a method for producing the bispecific antibody and therapeutic uses of the multispecific antibody in preventing or treating allergic diseases, inflammatory diseases, and eosinophilic diseases associated with IL-4, IL-13 and/or IL-5 are disclosed.
    Type: Application
    Filed: September 10, 2021
    Publication date: November 9, 2023
    Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Yong Sung KIM, Hae-Sim PARK, Jung Eun KIM, Keunok JUNG, Dong-Hyun LEE
  • Publication number: 20210403580
    Abstract: An antibody or antigen-binding fragment thereof, which binds with a high pM-level affinity to a human IL-4 receptor alpha chain that is a human IL-4 receptor, is provided. The antibody or antigen-binding fragment has a different epitope and a different antigen dissociation rate than existing antibodies. A nucleic acid encoding the antibody or antigen-binding fragment thereof, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or antigen-binding fragment thereof, a conjugate comprising the antibody or antigen-binding fragment thereof, a composition for preventing or treating inflammatory diseases, and a composition for diagnosing inflammatory diseases are disclosed.
    Type: Application
    Filed: November 7, 2019
    Publication date: December 30, 2021
    Applicant: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Yong Sung KIM, Hae-Sim PARK, Jung Eun KIM, Keunok JUNG
  • Publication number: 20210052675
    Abstract: Provided are vesicles derived from bacteria of the genus Lactococcus and a use thereof, and the inventors experimentally confirmed that the vesicles were significantly reduced in samples obtained from patients with diabetes, myocardial infarction, atrial fibrillation, stroke, renal failure, Parkinson's disease and depression, compared with a normal individual, and the vesicles inhibited the secretion of inflammation mediators caused by pathogenic vesicles. Therefore, it is expected that the vesicles derived from bacteria of the genus Lactococcus can be effectively used for a method of diagnosing diabetes, myocardial infarction, atrial fibrillation, stroke, renal failure, Parkinson's disease or depression, and a composition for preventing or treating the disease or inflammatory disease.
    Type: Application
    Filed: February 1, 2019
    Publication date: February 25, 2021
    Applicants: MD HEALTHCARE INC., AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Yoon-Keun KIM, Hae-Sim PARK